"H.R. 460 would allow more patients to access biologic drugs by limiting the patient cost-sharing burden that can be imposed for these treatments. It would limit cost sharing for treatments placed in a specialty drug tier (typically Tier IV or higher) to the highest cost-sharing a plan requires for drugs in its most expensive non-preferred brand drug tier (typically Tier III)."
The ACR has a pre written email that you can personalize. You can also find your Representative and email them, or if you prefer print out and send them a letter.